{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030494","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.884649+00:00","generated_at":"2026-06-05T04:37:25.583169+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cara Therapeutics reports Q4 net loss $0.59/share; prioritizes NP program, cash runway extended to 2026","bullets":["Net loss Q4 $32.3M ($0.59 per share) vs $30.3M ($0.56) prior year; full year loss $118.5M ($2.19) vs $85.5M ($1.59).","Total revenue Q4 $3.0M (down from $3.3M); FY 2023 $21.0M (down from $41.9M) on lower KORSUVA injection sales.","Completed enrollment of KOURAGE 1 Part A (214 patients); topline efficacy/safety data expected Q3 2024.","KORSUVA injection Q4 net sales $5.0M; TDAPA expires March 31, 2024; future reimbursement under ESRD PPS bundle.","Cash $100.8M at Dec 31, 2023; cash runway extended to 2026 via clinical prioritization, RIF, and HCR royalty deal ($36.5M net)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030494","json":"https://secwatch.observer/filing/0001104659-24-030494.json","markdown":"https://secwatch.observer/filing/0001104659-24-030494.md","text":"https://secwatch.observer/filing/0001104659-24-030494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924030494/0001104659-24-030494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924030494/tm247839d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:37:25.583169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea669b7cc4095f0f42fdfd6a7a4f6c5e06a5c1b9","claim":"Tvardi Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $3.0 million, net income $32.3 million, EPS $(0.59) per basic and diluted share.","evidence_excerpt":"For the fourth quarter of 2023, net loss was $32.3 million, or $(0.59) per basic and diluted share, compared to net loss of $30.3 million, or $(0.56) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $3.0 million and $3.3 million for the three months ended December 31, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924030494/0001104659-24-030494-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$3.0 million"},{"label":"Net income","value":"$32.3 million"},{"label":"EPS","value":"$(0.59) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}